A ‘Game Changer’ for Patients With Esophageal Cancer - The …
WEBMar 31, 2021 — Now a large clinical trial offers hope, finding that a drug that unleashes the immune system to attack cancer cells can double the disease-free survival times in …
New Gastric & Esophageal Cancer Treatment Breakthrough
WEBMar 23, 2022 — There are new, FDA-authorized treatment options for people facing esophageal and gastric (stomach) cancer, thanks to clinical trials at Memorial Sloan Kettering that combined immunotherapy with standard treatments.
Immunotherapy Improves Survival in Advanced Esophageal Cancer
WEBJun 17, 2021 — In people with advanced esophageal cancer, combining nivolumab (Opdivo) with either chemotherapy or ipilimumab (Yervoy) improved how long they lived, according to results from a large clinical trial.
FLOT Improves Survival in Locally Advanced Esophageal Cancer
WEBJul 9, 2024 — In the new trial, dubbed ESOPEC and funded by the German Research Foundation, 438 people with locally advanced esophageal cancer were randomly assigned to receive either perioperative chemotherapy with the FLOT regimen or neoadjuvant chemoradiation with the CROSS regimen.
Esophageal cancer is one of the deadliest cancers
WEBMar 31, 2022 — By Dana Sparks. The sixth most common cause of cancer deaths world-wide, esophageal cancer occurs in the esophagus — a long, hollow tube that runs from the throat to the stomach — and can occur anywhere along the esophagus. Men are more likely to develop esophageal cancer than women.
New Immunotherapy Combinations for Patients with Esophageal Cancer
WEBResults from a new phase III study found that combining PD-L1and TIGIT inhibitors plus chemotherapy in the first-line setting prolongs survival in an Asian population of patients with metastatic or locally advanced esophageal squamous cell carcinoma.
Nivolumab Combination Therapy in Advanced Esophageal …
WEBFeb 2, 2022 — Esophageal cancer causes more than half a million cancer-related deaths worldwide each year, 1 with squamous-cell carcinoma accounting for approximately 85% of cases. 2 Many esophageal cancers...
Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating ...
WEB3 days ago — Esophageal Cancer KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either:
For Esophageal Cancer, Immunotherapy Likely to Play Larger Role
WEBOct 19, 2020 — For some people with advanced esophageal cancer, the immunotherapy drugs pembrolizumab (Keytruda) and nivolumab (Opdivo) are likely to become part of early treatment for the disease. In large clinical trials of each treatment, the drugs increased how long patients lived without their cancer getting worse.
Adjuvant Nivolumab in Resected Esophageal or …
WEBMar 31, 2021 — In patients with resected esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy, nivolumab adjuvant therapy was associated with a significantly longer...